Article
CETP genotype predicts increased mortality in statin-treated men with proven cardiovascular disease: an adverse pharmacogenetic interaction.
European heart journal - 1 Nov 2008
Regieli Jakub J, Jukema J Wouter, Grobbee Diederick E, Kastelein John J P, Kuivenhoven Jan Albert, Zwinderman Aeilko H, van der Graaf Yolanda, Bots Michiel L, Doevendans Pieter A
Abstract excerpt
AIMS: Inhibition of cholesteryl ester transfer protein (CETP) increases HDL-cholesterol. However, its combination with statins may increase mortality by factors incompletely understood. We previously observed that patients with intrinsically low CETP levels (carriers of the TaqIB-B2 allele) may have less benefit from statin therapy, and here tested this pharmacogenetic hypothesis on long-term outcomes. METHODS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.